Naoki Furuya

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

K. Kunimasa, Shinsaku Tokuda, K. Morimoto, 2024, Cancer letters.